<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The results of 32 patients who underwent transcranial monobloc frontofacial advancement by the senior author (Wolfe) are examined </plain></SENT>
<SENT sid="1" pm="."><plain>Fifteen of the patients were <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e>'s and 17 were <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e>'s, 14 of whom also underwent simultaneous facial bipartition </plain></SENT>
<SENT sid="2" pm="."><plain>The ages ranged from 7 months to 14 years </plain></SENT>
<SENT sid="3" pm="."><plain>Although a transcranial facial advancement carries with it substantial risks, with careful consideration of airway control, the anterior cranial base dura, and the retrofrontal dead space, the procedure is recommended for carefully selected patients </plain></SENT>
<SENT sid="4" pm="."><plain>The indications and contraindications for the procedure in various age groups are given </plain></SENT>
</text></document>